04/08/2025
In this episode of the BroadEYE Podcast, hosts Shawn Maloney and Dr. Bruno Fernandes dive into a fascinating discussion with Dr. Peter Campochiaro, a clinician-scientist at Johns Hopkins’ Wilmer Eye Institute, about the potential of N-acetylcysteine (NAC) as a treatment for retinitis pigmentosa (RP).
Dr. Campochiaro shares how his research journey began with unexpected findings in mouse models, revealing how excess oxygen in the retina—caused by the loss of rod photoreceptors in RP—leads to oxidative stress that damages surviving cone cells. This discovery paved the way for the NAC Attack clinical trial, a phase 3 study exploring whether NAC, a potent antioxidant, can slow cone degeneration and preserve vision in RP patients.
The conversation covers the science behind NAC, its safety profile, and why it was chosen over other antioxidants like glutathione or CoQ10. Shawn, who lives with late-stage RP, brings a personal perspective, while Bruno, an ophthalmologist, digs into the broader implications for retinal diseases. Dr. Campochiaro also addresses practical challenges, like NAC’s over-the-counter availability versus its regulated use, and cautions against self-medication without medical supervision.
The episode offers hope for RP patients while emphasizing the importance of awaiting trial results, expected in a couple of years, to confirm NAC’s efficacy and long-term safety.
In this episode of the BroadEYE Podcast, hosts Shawn Maloney and Dr. Bruno Fernandes dive into a fascinating discussion with Dr. Peter Campochiaro, a clinician-scientist at Johns Hopkins’ Wilmer Eye Institute, about the potential of N-acetylcysteine (NAC) as a treatment … NAC Attack Clinical Tri...
